Code System: CDCNHSN

The CDCNHSN code system is highly specialized to meet the needs of NHSN surveillance reporting, is undergoing changes, and is not recommended for creating value sets to be used outside of NHSN.

 

OID: 2.16.840.1.113883.6.277
Name: NHSN Surveillance System Codes (CDCNHSN)
Definition: A set of healthcare surveillance vocabulary concepts and associated identifiers intended solely for data submissions to the National Healthcare Safety Network (NHSN). Other uses are not recommended.
Version: 2020-11


NHSN Surveillance System Codes (CDCNHSN)
Code Description
2350-2 A new antimicrobial agent(s) is started, and is continued for >=4 days
2105-5 Abdominal aortic aneurysm repair
2107-1 Abdominal hysterectomy
2118-8 Abdominal surgery
1309-4 Active surgical site infection (SSI) detection method
1871-3 Active surveillance testing (AST) eligible patients
3193-0 Active surveillance testing (AST) organism monitored
1957-0 Acute onset of diarrhea (liquid stools for >12 hours)
1971-1 Acute pain, swelling, or tenderness of testes, epididymis, or prostate
1510-7 Admission (during the stay in which the surgery was performed)
1652-7 Admitting inpatient facility
2368-9 Adult students or trainees and volunteers
2301-0 All patients
1965-3 Allogeneic hematopoietic stem cell transplant (allo-SCT) with diarrhea
1964-6 Allogeneic hematopoietic stem cell transplant (allo-SCT) with grade >=3 gastrointestinal graft-versus-host disease (GI GVHD)
1205-4 Anterior and posterior
6140-8 Antimicrobial-coated catheter used
1959-6 Apnea, tachypnea, nasal flaring with retraction of chest wall or grunting
2108-9 Appendix surgery
1623-8 Arterial or venous infection
2402-6 Asymptomatic bacteremic UTI (ABUTI)
1101-5 Atlas-axis
1102-3 Atlas-axis/Cervical
3061-9 Atrial lines (right and left)
1651-9 Attending physician other than surgeon
1820-0 avibactam / ceftazidime
2037-0 Bacterial isolate tested for carbapenemase
2513-0 Bilateral infiltrates on chest x-ray
2109-7 Bile duct, liver or pancreatic surgery
3302-7 Birth weight 1001-1500 grams
3303-5 Birth weight 1501-2500 grams
3301-9 Birth weight 751-1000 grams
3304-3 Birth weight over 2500 grams
3300-1 Birth weight under 750 grams
1902-6 Blood culture not done or no organisms detected in blood
2500-7 Blood product was implicated in the adverse reaction
2339-0 Blood sample collected for culture
1798-8 Bone or joint infection
1908-3 Bradycardia or tachycardia
1601-4 Breast abscess or mastitis
2110-5 Breast surgery
1671-7 Bronchitis or tracheitis
1672-5 Burn infection
2308-5 Buttonhole cannulation
2029-7 C. difficile primary testing method used most often for this quarter
1795-4 C. difficile-associated disease (CDAD) infection
6122-6 Cap
2045-3 Carba NP
2049-5 Carbapenemase type
2111-3 Cardiac surgery
2114-7 Carotid endarterectomy
2501-5 Case definition match
1969-5 Catheter-graft hybrid
1818-4 ceftolozane / tazobactam
2031-3 Cell cytotoxicity neutralization assay
1002-5 Central line
3121-1 Central line exchanged over guidewire
1006-6 Central line including umbilical catheter
3108-8 Central line insertion practice (CLIP)
2016-4 CephR-Klebsiella
1103-1 Cervical
1104-9 Cervical/Dorsal/Dorsolumbar
2115-4 Cesarean section
1603-0 Clinical sepsis
3195-5 Clinical specialty
2116-2 Colon surgery
1944-8 Common commensal from >=2 blood cultures
3070-0 Common commensal from blood specimen(s) and antibiotics for >=5 days
3072-6 Common commensal from cerebrospinal fluid specimen and antibiotics for >=5 days
2303-6 Contamination
2337-4 Continuation of antimicrobial
6130-9 Contraindication type
1325-0 Cooperative infection prevention process between facilities
2112-1 Coronary artery bypass graft with both chest and donor site incisions
2113-9 Coronary artery bypass graft with chest incision only
2117-0 Craniotomy
2018-0 CRE-E. coli
2019-8 CRE-Enterobacter
2017-2 CRE-Klebsiella
2352-5 Criterion 1: positive culture from bronchoalveolar lavage without purulent respiratory secretions
2351-1 Criterion 1: positive culture from endotracheal aspirate without purulent respiratory secretions
2353-3 Criterion 1: positive culture from lung tissue without purulent respiratory secretions
2354-1 Criterion 1: positive culture from protected specimen brush without purulent respiratory secretions
2358-0 Criterion 2: organisms from bronchoalveolar lavage culture with purulent respiratory secretions
2357-2 Criterion 2: organisms from endotracheal aspirate culture with purulent respiratory secretions
2359-8 Criterion 2: organisms from lung tissue culture with purulent respiratory secretions
2360-1 Criterion 2: organisms from protected specimen brush culture with purulent respiratory secretions
2356-4 Criterion 2: organisms from sputum culture with purulent respiratory secretions
2355-9 Criterion 2: purulent respiratory secretions plus organism(s)
2363-2 Criterion 3: positive diagnostic test for Legionella species
2364-0 Criterion 3: positive diagnostic test for selected viral pathogens
2362-4 Criterion 3: positive test for lung histopathology
2361-0 Criterion 3: positive test for organism(s) identified from pleural fluid
2516-3 Criterion not otherwise specified
2346-5 Daily minimum FiO2 increase >=0.20 (20 points) for >=2 days
2347-3 Daily minimum PEEP increase >=3 cm H2O for >=2 days
1815-0 dalbavancin
1373-0 Date first admitted to facility
1673-3 Decubitus ulcer infection
1604-8 Deep incisional primary surgical site infection (SSI)
1605-5 Deep incisional secondary surgical site infection (SSI)
1821-8 delafloxacin
2333-3 Dialysis clinic
2514-8 Diffuse hemorrhage
1674-1 Disseminated infection
1105-6 Dorsal/Dorsolumbar
1607-1 Ear or mastoid infection (otitis externa, otitis media, otitis interna, mastoiditis)
2366-3 Employees (staff on facility payroll)
2030-5 Enzyme immunoassay (EIA) for toxin
3057-7 Epidermolysis bullosa during current admission
1334-2 Extremely preterm (<28 weeks)
1608-9 Eye infection, other than conjunctivitis
6133-3 Facility restrictions or safety concerns for chlorhexidine gluconate use in premature infants precludes its use
3542-8 Facility transfuses blood products treated with pathogen reduction technology
4103-8 Fellow
1814-3 fidaxomicin
3498-3 First discovery
1938-0 Fourfold rise in Legionella pneumophila antibody titer
1935-6 Fourfold rise in paired sera for pathogen
1940-6 Fungi or Pneumocystis carinii from lower respiratory tract specimen
2119-6 Gallbladder surgery
2120-4 Gastric surgery
1609-7 Gastrointestinal tract infection (esophagus, stomach, small and large bowel, and rectum) excluding gastroenteritis and appendicitis
2033-9 Glutamate dehydrogenase (GDH) antigen plus enzyme immunoassay (EIA) for toxin
2035-4 Glutamate dehydrogenase (GDH) plus enzyme immunoassay (EIA) for toxin, followed by nucleic acid amplification test (NAAT) for discrepant results
2034-7 Glutamate dehydrogenase (GDH) plus nucleic acid amplification test (NAAT)
1929-9 Greater than or equal to 2 positive urine cultures with >=100 cfu/ml of same uropathogen from non-voided specimen
1931-5 Greater than or equal to 2 positive urine cultures with >=100,000 cfu/ml with no more than 2 organisms
1923-3 Greater than or equal to 5% bronchoalveolar lavage cells with bacteria
3109-6 Hand hygiene
2121-2 Heart transplant
3062-7 Hemodialysis reliable outflow (HERO) catheter
2543-7 Hemovigilance module – monthly reporting denominator
2106-3 Herniorrhaphy
2101-4 Hip prosthesis
1956-2 Histopathologic exam with abscess formation or lung parenchyma invasion by fungal hyphae
2332-5 Hospital (on the day of or the day following admission) or Emergency Department
1645-1 Hospital transfer/admission
1416-7 HPRO: Hemi: Partial Primary
1418-3 HPRO: Hemi: Partial Revision
1417-5 HPRO: Hemi: Total Revision
1421-7 HPRO: Resurfacing: Partial Primary
1422-5 HPRO: Resurfacing: Partial Revision
1419-1 HPRO: Resurfacing: Total Primary
1420-9 HPRO: Resurfacing: Total Revision
1415-9 HPRO: Total: Partial Revision
1413-4 HPRO: Total: Total Primary
1414-2 HPRO: Total: Total Revision
1924-0 Imaging test evidence of infection
2052-9 Imipenemase
2502-3 Imputability of adverse reaction to transfusion
2503-1 Imputability of death to transfusion
2307-7 Imputability of positive blood culture to suspected source
1967-9 Incision deliberately opened or drained
1675-8 Infant pustulosis
1656-8 Infection first reported source
3188-0 Infection occurred post-procedure
1797-0 Infection of the ear, eyes, nose, or throat
1237-7 Infection present at time of surgery (PATOS)
2344-2 Infection-related ventilator-associated complication (IVAC)
1610-5 Intraabdominal infection, not specified elsewhere including gallbladder, bile ducts, liver (excluding viral hepatitis), spleen, pancreas, peritoneum, subphrenic or subdiaphragmatic space, or other intraabdominal tissue or area not specified elsewhere
3063-5 Intra-aortic balloon pump (IABP) device
1611-3 Intracranial infection (brain abscess, subdural or epidural infection, encephalitis)
2306-9 Intravenous injection of antifungal substance
1819-2 isavuconazonium
2048-7 Isolate tested positive for carbapenemase
4100-4 IV team
1612-1 Joint or bursa infection
2122-0 Kidney surgery
2123-8 Kidney transplant
2050-3 Klebsiella pneumoniae carbapenemase
2124-6 Knee prosthesis
3055-1 Known or suspected Munchausen syndrome by proxy during current admission
1409-2 KPRO: Hemi: Partial Primary
1412-6 KPRO: Hemi: Partial Revision
1411-8 KPRO: Hemi: Total Revision
1408-4 KPRO: Total: Partial Revision
1406-8 KPRO: Total: Total Primary
1407-6 KPRO: Total: Total Revision
1613-9 Laboratory-confirmed bloodstream infection
2125-3 Laminectomy
6112-7 Large sterile drape
3002-3 Last physical overnight location of patient immediately prior to arriving into facility
1937-2 Legionella pneumophila serogroup 1 antigens in urine
2367-1 Licensed independent practitioners: physicians, advanced practice nurses, and physician assistants
2126-1 Limb amputation
2127-9 Liver transplant
1920-8 Localized swelling
2341-2 Location of mechanical ventilation initiation
2325-9 Loss of vascular access
1106-4 Lumbar/Lumbosacral
6110-1 Mask
1939-8 Matching positive blood and sputum cultures with Candida species
2010-7 MDR-Acinetobacter
2318-4 MDRO or C. difficile infection
4102-0 Medical staff not otherwise specified
1615-4 Meningitis or ventriculitis
2046-1 Metallo-beta-lactamase gradient strip
2047-9 Metallo-beta-lactamase screen
1336-7 Moderate to late preterm (32 to <37 weeks)
2044-6 Modified Hodge test
1942-2 More than 15 colonies cultured from intravascular cannula tip using semi-quantitative culture method
1792-1 Multi-drug resistant organism (MDRO) infection
1602-2 Myocarditis or pericarditis
2515-5 Nausea/vomiting
2128-7 Neck surgery
3066-8 Neonatal Laboratory Confirmed Bloodstream Infection 1 (NLCBI 1)
3067-6 Neonatal Laboratory Confirmed Bloodstream Infection 2 (NLCBI 2)
3068-4 Neonatal Laboratory Confirmed Meningitis 1 (NLCM 1)
3069-2 Neonatal Laboratory Confirmed Meningitis 2 (NLCM 2)
2336-6 New antibiotic start
2051-1 New Delhi metallo-beta-lactamase
1907-5 New onset or change in sputum, increased secretions or increased suctioning
1903-4 New onset/change in sputum
1904-2 New onset/worsening cough, dyspnea, tachypnea
1925-7 New or progressive and persistent infiltrate
2335-8 New outpatient start or continuation of inpatient course
1676-6 Newborn circumcision infection
3540-2 No hemovigilance adverse reactions reported this month
3541-0 No hemovigilance incidents reported this month
1311-0 No location change
3119-7 No pathogen identified
3064-3 Non-accessed central line (not accessed nor inserted during the hospitalization)
3189-8 Non-autologous transplant
2055-2 Nonspecific carbapenemase activity
2056-0 Nonspecific metallo-beta-lactamase activity
1119-7 Non-tunneled (dialysis)
1120-5 Non-tunneled (other than dialysis)
2103-0 Not an NHSN operation
1901-8 Not cultured
2032-1 Nucleic acid amplification test (NAAT)
2057-8 Nucleic acid amplification test (NAAT) plus enzyme immunoassay (EIA), if NAAT positive (2-step algorithm)
1862-2 Number of admissions
1831-7 Number of admissions adjusted for C. difficile reporting
1828-3 Number of admissions adjusted for MDRO reporting (for inpatient location)
1371-4 Number of admissions on C. difficile treatment
1641-0 Number of admissions with an order for a prophylactic intravenous antibiotic that was administered on time
1642-8 Number of admissions with an order for a prophylactic intravenous antibiotic that was not administered on time
1643-6 Number of admissions with no order for a prophylactic intravenous antibiotic
3499-1 Number of adverse reactions
1834-1 Number of airway pressure release ventilation (APRV) days
3533-7 Number of aliquots transfused: Plasma: Apheresis: Psoralen-treated
3536-0 Number of aliquots transfused: Plasma: Apheresis: Riboflavin-treated
3524-6 Number of aliquots transfused: Plasma: Whole blood-derived: Psoralen-treated
3527-9 Number of aliquots transfused: Plasma: Whole blood-derived: Riboflavin-treated
3424-9 Number of aliquots transfused: Platelets: Apheresis: Irradiated
3428-0 Number of aliquots transfused: Platelets: Apheresis: Irradiated or leukocyte-reduced
3426-4 Number of aliquots transfused: Platelets: Apheresis: Leukocyte-reduced
3492-6 Number of aliquots transfused: Platelets: Apheresis: Not irradiated or leukocyte-reduced
3515-4 Number of aliquots transfused: Platelets: Apheresis: Psoralen-treated
3569-1 Number of aliquots transfused: Platelets: Apheresis: Psoralen-treated and in plasma
3572-5 Number of aliquots transfused: Platelets: Apheresis: Psoralen-treated and in platelet additive solution
3518-8 Number of aliquots transfused: Platelets: Apheresis: Riboflavin-treated
3575-8 Number of aliquots transfused: Platelets: Apheresis: Riboflavin-treated and in plasma
3578-2 Number of aliquots transfused: Platelets: Apheresis: Riboflavin-treated and in platelet additive solution
3412-4 Number of aliquots transfused: Red Blood Cells: Apheresis: Irradiated
3416-5 Number of aliquots transfused: Red Blood Cells: Apheresis: Irradiated or leukocyte-reduced
3414-0 Number of aliquots transfused: Red Blood Cells: Apheresis: Leukocyte-reduced
3479-3 Number of aliquots transfused: Red Blood Cells: Apheresis: Not irradiated or leukocyte-reduced
3560-0 Number of aliquots transfused: Red Blood Cells: Apheresis: Riboflavin-treated
3557-6 Number of aliquots transfused: Red Blood Cells: Apheresis: S-303-treated
3404-1 Number of aliquots transfused: Red Blood Cells: Whole blood-derived: Irradiated
3408-2 Number of aliquots transfused: Red Blood Cells: Whole blood-derived: Irradiated and leukocyte-reduced
3406-6 Number of aliquots transfused: Red Blood Cells: Whole blood-derived: Leukocyte-reduced
3472-8 Number of aliquots transfused: Red Blood Cells: Whole blood-derived: Not irradiated or leukocyte-reduced
3551-9 Number of aliquots transfused: Red Blood Cells: Whole blood-derived: Riboflavin-treated
3548-5 Number of aliquots transfused: Red Blood Cells: Whole blood-derived: S-303-treated
2409-1 Number of blood cultures performed
1372-2 Number of C. difficile treatment starts
1833-3 Number of central line days
1854-9 Number of central line days including umbilical catheter
2310-1 Number of chronic hemodialysis patients: fistula
2312-7 Number of chronic hemodialysis patients: graft
2314-3 Number of chronic hemodialysis patients: non-tunneled central line
2315-0 Number of chronic hemodialysis patients: other access device
2313-5 Number of chronic hemodialysis patients: tunneled central line
3565-9 Number of discards: Cryoprecipitate: Psoralen-treated
3567-5 Number of discards: Cryoprecipitate: Riboflavin-treated
3534-5 Number of discards: Plasma: Apheresis: Psoralen-treated
3537-8 Number of discards: Plasma: Apheresis: Riboflavin-treated
3525-3 Number of discards: Plasma: Whole blood-derived: Psoralen-treated
3528-7 Number of discards: Plasma: Whole blood-derived: Riboflavin-treated
3494-2 Number of discards: Platelets: Apheresis: Irradiated
3496-7 Number of discards: Platelets: Apheresis: Irradiated or leukocyte-reduced
3495-9 Number of discards: Platelets: Apheresis: Leukocyte-reduced
3493-4 Number of discards: Platelets: Apheresis: Not irradiated or leukocyte-reduced
3516-2 Number of discards: Platelets: Apheresis: Psoralen-treated
3570-9 Number of discards: Platelets: Apheresis: Psoralen-treated and in plasma
3573-3 Number of discards: Platelets: Apheresis: Psoralen-treated and in platelet additive solution
3519-6 Number of discards: Platelets: Apheresis: Riboflavin-treated
3576-6 Number of discards: Platelets: Apheresis: Riboflavin-treated and in plasma
3579-0 Number of discards: Platelets: Apheresis: Riboflavin-treated and in platelet additive solution
3487-6 Number of discards: Platelets: Whole blood-derived: Irradiated
3489-2 Number of discards: Platelets: Whole blood-derived: Irradiated and leukocyte-reduced
3488-4 Number of discards: Platelets: Whole blood-derived: Leukocyte-reduced
3486-8 Number of discards: Platelets: Whole blood-derived: Not irradiated or leukocyte-reduced
3507-1 Number of discards: Platelets: Whole blood-derived: Psoralen-treated
3510-5 Number of discards: Platelets: Whole blood-derived: Riboflavin-treated
3481-9 Number of discards: Red Blood Cells: Apheresis: Irradiated
3483-5 Number of discards: Red Blood Cells: Apheresis: Irradiated or leukocyte-reduced
3482-7 Number of discards: Red Blood Cells: Apheresis: Leukocyte-reduced
3480-1 Number of discards: Red Blood Cells: Apheresis: Not irradiated or leukocyte-reduced
3561-8 Number of discards: Red Blood Cells: Apheresis: Riboflavin-treated
3558-4 Number of discards: Red Blood Cells: Apheresis: S-303-treated
3474-4 Number of discards: Red Blood Cells: Whole blood-derived: Irradiated
3476-9 Number of discards: Red Blood Cells: Whole blood-derived: Irradiated and leukocyte-reduced
3475-1 Number of discards: Red Blood Cells: Whole blood-derived: Leukocyte-reduced
3473-6 Number of discards: Red Blood Cells: Whole blood-derived: Not irradiated or leukocyte-reduced
3552-7 Number of discards: Red Blood Cells: Whole blood-derived: Riboflavin-treated
3549-3 Number of discards: Red Blood Cells: Whole blood-derived: S-303-treated
1863-0 Number of encounters
1832-5 Number of encounters adjusted for C. difficile reporting
1829-1 Number of encounters adjusted for MDRO reporting
1333-4 Number of episodes of mechanical ventilation (EMV) days
2311-9 Number of fistula patients who undergo buttonhole cannulation
1878-8 Number of incident cases identified by monitoring (clinical positive)
1826-7 Number of new episodes of mechanical ventilation (EMV)
1867-1 Number of observations in which gown and gloves were used
1864-8 Number of observations in which hand hygiene was indicated
1865-5 Number of observations in which hand hygiene was performed
1866-3 Number of observations in which the use of gown and gloves was indicated
1851-5 Number of patient days
1830-9 Number of patient days adjusted for C. difficile reporting (for inpatient location)
1827-5 Number of patient days adjusted for MDRO reporting (for inpatient location)
3436-3 Number of patient samples collected for type and screen or crossmatch
2525-4 Number of patient-present days
1872-1 Number of patients eligible for monitoring at admission/transfer in
1874-7 Number of patients eligible for monitoring at discharge/transfer out
1860-6 Number of patients meeting high risk criteria and offered influenza vaccination but declining because of having medical contraindication
1858-0 Number of patients meeting high risk criteria and previously vaccinated for influenza during current influenza season
1861-4 Number of patients meeting high risk criteria and receiving vaccination during admission
1856-4 Number of patients meeting high risk criteria for influenza vaccination
1859-8 Number of patients meeting high risk criteria for influenza vaccination and offered influenza vaccination but declining for reasons other than medical contraindication
1873-9 Number of patients on which monitoring was performed at admission/transfer in
1875-4 Number of patients on which monitoring was performed at discharge/transfer out
1857-2 Number of patients previously vaccinated for influenza during current influenza season
3306-8 Number of permanent central line days
1876-2 Number of prevalent cases identified by monitoring (clinical positive)
1877-0 Number of prevalent cases previously known
3305-0 Number of temporary central line days
2524-7 Number of therapy days
1889-5 Number of total facility admissions (for inpatient location)
1890-3 Number of total facility encounters (for outpatient location)
1888-7 Number of total facility patient days (for inpatient location)
3564-2 Number of units transfused: Cryoprecipitate: Psoralen-treated
3566-7 Number of units transfused: Cryoprecipitate: Riboflavin-treated
3532-9 Number of units transfused: Plasma: Apheresis: Psoralen-treated
3535-2 Number of units transfused: Plasma: Apheresis: Riboflavin-treated
3523-8 Number of units transfused: Plasma: Whole blood-derived: Psoralen-treated
3526-1 Number of units transfused: Plasma: Whole blood-derived: Riboflavin-treated
3423-1 Number of units transfused: Platelets: Apheresis: Irradiated
3427-2 Number of units transfused: Platelets: Apheresis: Irradiated or leukocyte-reduced
3425-6 Number of units transfused: Platelets: Apheresis: Leukocyte-reduced
3491-8 Number of units transfused: Platelets: Apheresis: Not irradiated or leukocyte-reduced
3514-7 Number of units transfused: Platelets: Apheresis: Psoralen-treated
3568-3 Number of units transfused: Platelets: Apheresis: Psoralen-treated and in plasma
3571-7 Number of units transfused: Platelets: Apheresis: Psoralen-treated and in platelet additive solution
3517-0 Number of units transfused: Platelets: Apheresis: Riboflavin-treated
3574-1 Number of units transfused: Platelets: Apheresis: Riboflavin-treated and in plasma
3577-4 Number of units transfused: Platelets: Apheresis: Riboflavin-treated and in platelet additive solution
3418-1 Number of units transfused: Platelets: Whole blood-derived: Irradiated
3420-7 Number of units transfused: Platelets: Whole blood-derived: Irradiated and leukocyte-reduced
3419-9 Number of units transfused: Platelets: Whole blood-derived: Leukocyte-reduced
3485-0 Number of units transfused: Platelets: Whole blood-derived: Not irradiated or leukocyte-reduced
3505-5 Number of units transfused: Platelets: Whole blood-derived: Psoralen-treated
3508-9 Number of units transfused: Platelets: Whole blood-derived: Riboflavin-treated
3411-6 Number of units transfused: Red Blood Cells: Apheresis: Irradiated
3415-7 Number of units transfused: Red Blood Cells: Apheresis: Irradiated or leukocyte-reduced
3413-2 Number of units transfused: Red Blood Cells: Apheresis: Leukocyte-reduced
3478-5 Number of units transfused: Red Blood Cells: Apheresis: Not irradiated or leukocyte-reduced
3559-2 Number of units transfused: Red Blood Cells: Apheresis: Riboflavin-treated
3556-8 Number of units transfused: Red Blood Cells: Apheresis: S-303-treated
3403-3 Number of units transfused: Red Blood Cells: Whole blood-derived: Irradiated
3407-4 Number of units transfused: Red Blood Cells: Whole blood-derived: Irradiated and leukocyte-reduced
3405-8 Number of units transfused: Red Blood Cells: Whole blood-derived: Leukocyte-reduced
3471-0 Number of units transfused: Red Blood Cells: Whole blood-derived: Not irradiated or leukocyte-reduced
3550-1 Number of units transfused: Red Blood Cells: Whole blood-derived: Riboflavin-treated
3547-7 Number of units transfused: Red Blood Cells: Whole blood-derived: S-303-treated
1853-1 Number of urinary catheter days
1852-3 Number of ventilator days
3005-6 Nursing Home/Skilled Nursing Facility
3056-9 Observed or suspected patient injection into vascular line(s) within the BSI infection window
1909-1 Occult or gross blood in stools (with no rectal fissure)
2202-0 On admission and on discharge/transfer
2201-2 On admission only
1930-7 One positive culture with <=100,000 cfu/ml of a single uropathogen in patient being treated with an effective antimicrobial agent for UTI
2403-4 One positive culture with >=1,000 cfu/ml and <100,000 cfu/ml with no more than 2 species of microorganisms
1927-3 One positive culture with >=100,000 cfu/ml with no more than 2 species of microorganisms
2302-8 Only patients with no prior documentation of colonization or infection
2129-5 Open reduction of fracture
1616-2 Oral cavity infection (mouth, tongue, or gums)
1650-1 Order for prophylactic intravenous antibiotic not administered on time
1640-2 Organ/space
1946-3 Organism(s) identified from pleural fluid
1817-6 oritavancin
2369-7 Other contract personnel
1905-9 Other evidence of infection found
1614-7 Other infections of lower respiratory tract, other than pneumonia
1617-0 Other infections of the male or female reproductive tract (epididymis, testes, prostate, vagina, ovaries, uterus, or other deep pelvic tissues, excluding endometritis or vaginal cuff infections)
1618-8 Other infections of the urinary tract (kidney, ureter, bladder, urethra, or tissue surrounding the retroperitoneal or perinephric space)
3006-4 Other inpatient healthcare setting (e.g., Acute Care Hospital, LTAC, Rehabilitation, etc.)
2104-8 Other operations
1941-4 Other positive laboratory tests
1906-7 Other signs and symptoms
2407-5 Other than primary
2130-3 Ovarian surgery
2054-5 Oxacillinase-48-like
2131-1 Pacemaker surgery
2517-1 Pain not otherwise specified
1960-4 Pain or tenderness
1312-8 Passive surgical site infection (SSI) detection method
3004-9 Patient discharged from another facility in the past 4 weeks
6132-5 Patient has a documented/known allergy/reaction to chlorhexidine gluconate-based products that would preclude its use
6131-7 Patient is less than 2 months of age – chlorhexidine gluconate is to be used with caution in patients less than 2 months of age
2342-6 Patient on airway pressure release ventilation (APRV) or a related mode of mechanical ventilation at the time of VAE
1326-8 Patient or caregiver contacts facility to report
1654-3 Patient or family member
1327-6 Patient returns to outpatient facility for follow-up
2041-2 PCR: Imipenemase
2039-6 PCR: Klebsiella pneumoniae carbapenemase
2040-4 PCR: New Delhi metallo-beta-lactamase
2043-8 PCR: Oxacillinase-48 like
2042-0 PCR: Verona integron-encoded metallo-beta-lactamase
2213-7 Performer was a member of PICC/IV team
3163-3 Performs direct patient care
3060-1 Peripheral intravenous or midline catheter
2132-9 Peripheral vascular bypass surgery
3115-3 Peripherally inserted central catheter (PICC)
1970-3 Periprosthetic joint infection
1003-3 Permanent central line
3007-2 Personal residence/residential care
4101-2 Physician assistant
1963-8 Physician diagnosis of this event type
1962-0 Physician institutes appropriate antimicrobial therapy
2212-9 PICC team
1926-5 Pneumatoceles (in <=1 year old)
1626-1 Pneumonia 1 (PNU1)
1631-1 Pneumonia 2 (PNU2)
1632-9 Pneumonia 3 (PNU3)
1955-4 Positive blood culture
1952-1 Positive culture
1966-1 Positive culture from >=2 separate tissue or fluid samples from affected joint
1953-9 Positive culture of pathogen
1954-7 Positive culture of skin contaminant
1948-9 Positive culture of virus or Chlamydia
1936-4 Positive culture or microimmunofluorescence of Legionella species
1934-9 Positive detection of viral antigen or antibody
1928-1 Positive dipstick for leukocyte esterase or nitrate
1943-0 Positive Gram stain when culture is negative or not done
1950-5 Positive microimmunofluorescence test for Chlamydia
1949-7 Positive PCR for Chlamydia or Mycoplasma
1947-1 Positive quantitative culture from lower respiratory tract (LRT) specimen
2345-0 Possible ventilator-associated pneumonia (PVAP)
1323-5 Post-discharge patient letter
1324-3 Post-discharge patient phone call
1322-7 Post-discharge surgeon survey
1505-7 Post-discharge surveillance
2406-7 Primary
2133-7 Prostate surgery
3059-3 Pus present at vascular specimen collection site and matching organism identified in blood and from site-specific specimen(s)
2305-1 Pus, redness, or increased swelling
1921-6 Rales or bronchial breath sounds
2518-9 Rash not otherwise specified
1517-2 Readmission to facility other than where procedure was performed
1516-4 Readmission to facility where procedure was performed
2504-9 Received non-irradiated blood in the 2 months preceding the reaction
3071-8 Recognized pathogen from cerebrospinal fluid specimen
1951-3 Recognized pathogen from one or more blood cultures
3104-7 Recorder was performer
2134-5 Rectal surgery
2135-2 Refusion of spine
2404-2 Removed within 48 hours prior
1329-2 Report from another facility (inpatient, health department, emergency department, etc.)
1341-7 Report No Events: Antimicrobial Resistance (AR)
3052-8 Report No Events: Dialysis: intravenous antimicrobial start
3053-6 Report No Events: Dialysis: positive blood culture
3054-4 Report No Events: Dialysis: pus, redness, or increased swelling at vascular access site
3011-4 Report No Events: ICU: CAUTI
3010-6 Report No Events: ICU: CLABSI
1338-3 Report No Events: ICU: PedVAE
3013-0 Report No Events: ICU: PedVAP
3012-2 Report No Events: ICU: VAE
3050-2 Report No Events: Infection Surveillance: C. difficile
3035-3 Report No Events: Infection Surveillance: CephR Klebsiella
3038-7 Report No Events: Infection Surveillance: CRE-E. coli
3041-1 Report No Events: Infection Surveillance: CRE-Enterobacter
3044-5 Report No Events: Infection Surveillance: CRE-Klebsiella
3047-8 Report No Events: Infection Surveillance: MDR-Acinetobacter
3029-6 Report No Events: Infection Surveillance: MRSA
1306-0 Report No Events: Infection Surveillance: MSSA
3032-0 Report No Events: Infection Surveillance: VRE
3051-0 Report No Events: LabID Event (All specimens): C. difficile
3036-1 Report No Events: LabID Event (All specimens): CephR Klebsiella
3039-5 Report No Events: LabID Event (All specimens): CRE-E. coli
3042-9 Report No Events: LabID Event (All specimens): CRE-Enterobacter
3045-2 Report No Events: LabID Event (All specimens): CRE-Klebsiella
3048-6 Report No Events: LabID Event (All specimens): MDR-Acinetobacter
3030-4 Report No Events: LabID Event (All specimens): MRSA
1307-8 Report No Events: LabID Event (All specimens): MSSA
3033-8 Report No Events: LabID Event (All specimens): VRE
3037-9 Report No Events: LabID Event (Blood specimens only): CephR Klebsiella
3040-3 Report No Events: LabID Event (Blood specimens only): CRE-E. coli
3043-7 Report No Events: LabID Event (Blood specimens only): CRE-Enterobacter
3046-0 Report No Events: LabID Event (Blood specimens only): CRE-Klebsiella
3049-4 Report No Events: LabID Event (Blood specimens only): MDR-Acinetobacter
3031-2 Report No Events: LabID Event (Blood specimens only): MRSA
1308-6 Report No Events: LabID Event (Blood specimens only): MSSA
3034-6 Report No Events: LabID Event (Blood specimens only): VRE
3016-3 Report No Events: NICU: CLABSI: 1001-1500 grams
3017-1 Report No Events: NICU: CLABSI: 1501-2500 grams
3015-5 Report No Events: NICU: CLABSI: 751-1000 grams
3018-9 Report No Events: NICU: CLABSI: over 2500 grams
3014-8 Report No Events: NICU: CLABSI: under 750 grams
1316-9 Report No Events: NICU: PedVAE: birth weight 1001-1500 grams
1317-7 Report No Events: NICU: PedVAE: birth weight 1501-2500 grams
1314-4 Report No Events: NICU: PedVAE: birth weight 751-1000 grams
1318-5 Report No Events: NICU: PedVAE: birth weight over 2500 grams
1313-6 Report No Events: NICU: PedVAE: birth weight under 750 grams
1319-3 Report No Events: NICU: PedVAE: Extremely preterm (<28 weeks)
1331-8 Report No Events: NICU: PedVAE: Moderate to late preterm (32 to <37 weeks)
1332-6 Report No Events: NICU: PedVAE: Term (>=37 weeks)
1330-0 Report No Events: NICU: PedVAE: Very preterm (28 to <32 weeks)
3021-3 Report No Events: NICU: PedVAP: 1001-1500 grams
3022-1 Report No Events: NICU: PedVAP: 1501-2500 grams
3020-5 Report No Events: NICU: PedVAP: 751-1000 grams
3023-9 Report No Events: NICU: PedVAP: over 2500 grams
3019-7 Report No Events: NICU: PedVAP: under 750 grams
1340-9 Report No Events: Same Day Outcome Measures
3026-2 Report No Events: SCA: CAUTI
3025-4 Report No Events: SCA: PCLAB
1339-1 Report No Events: SCA: PedVAE
3028-8 Report No Events: SCA: PedVAP
3024-7 Report No Events: SCA: TCLAB
3027-0 Report No Events: SCA: VAE
1796-2 Reproductive tract infection
1370-6 Resident admissions
1369-8 Resident days
1375-5 Resident on antibiotic therapy for this specific organism at the time of transfer
1374-8 Resident transferred from acute care facility in past 4 weeks
1321-9 Review of patient’s medical record
1239-3 Revision associated with prior infection at index joint
1653-5 Routine follow-up at outpatient facility
3192-2 Seasons immunized
3111-2 Secondary bloodstream infection
2102-2 Shunt for dialysis
1968-7 Sinus tract
2321-8 Site of non-tunneled central line, dialysis
2322-6 Site of tunneled central line, dialysis
2136-0 Small bowel surgery
1677-4 Soft tissue, muscle, lymph node, or salivary gland infection
3114-6 Solution(s) had dried
1619-6 Spinal abscess without meningitis
2137-8 Spinal fusion
2138-6 Spleen surgery
6113-5 Sterile gloves
6111-9 Sterile gown
1884-6 Summary data reporting active surveillance testing (AST)
2410-9 Summary data reporting antimicrobial resistance patterns at a facility
1887-9 Summary data reporting antimicrobial usage
1879-6 Summary data reporting catheter and ventilator use in a ICU/other
1881-2 Summary data reporting catheter and ventilator use in a NICU
1880-4 Summary data reporting catheter and ventilator use in a SCA
1891-1 Summary data reporting MDRO and CDI LabID Event for LTCF
1657-6 Summary data reporting outpatient procedure component events at a facility
2316-8 Summary data reporting vascular access types for chronic hemodialysis patients
1620-4 Superficial incisional primary surgical site infection (SSI)
1621-2 Superficial incisional secondary surgical site infection (SSI)
1328-4 Surgeon contacts facility to report
1238-5 Surgical site infection (SSI) detected using the NHSN ICD-code based admit and readmit SSI surveillance toolkit
1625-3 Symptomatic UTI (SUTI)
1816-8 tedizolid
2348-1 Temperature >38°C or <36°C
1005-8 Temporary central line
1337-5 Term (>=37 weeks)
2139-4 Thoracic surgery
2140-2 Thyroid and/or parathyroid surgery
1870-5 Timing of active surveillance testing (AST)
5105-2 To address a new indication for a central line
5107-8 To replace an existing central line where infection was suspected
5106-0 To replace an existing, malfunctioning central line
3538-6 Total crossmatch procedures
1644-4 Total number of admissions with a primary CPT code in this procedure category
3432-2 Total number of aliquots transfused: Plasma: Apheresis
3530-3 Total number of aliquots transfused: Plasma: Apheresis: Psoralen- and Riboflavin-treated
3430-6 Total number of aliquots transfused: Plasma: Whole blood-derived
3521-2 Total number of aliquots transfused: Plasma: Whole blood-derived: Psoralen- and Riboflavin-treated
3422-3 Total number of aliquots transfused: Platelets: Apheresis
3512-1 Total number of aliquots transfused: Platelets: Apheresis: Psoralen- and Riboflavin-treated
3410-8 Total number of aliquots transfused: Red Blood Cells: Apheresis
3554-3 Total number of aliquots transfused: Red Blood Cells: Apheresis: S-303- and Riboflavin-treated
3402-5 Total number of aliquots transfused: Red Blood Cells: Whole blood-derived
3545-1 Total number of aliquots transfused: Red Blood Cells: Whole blood-derived: S-303- and Riboflavin-treated
3468-6 Total number of aliquots transfused: Whole Blood
3501-4 Total number of discards: Cryoprecipitate
3563-4 Total number of discards: Cryoprecipitate: Psoralen- and Riboflavin-treated
3500-6 Total number of discards: Plasma: Apheresis
3531-1 Total number of discards: Plasma: Apheresis: Psoralen- and Riboflavin-treated
3497-5 Total number of discards: Plasma: Whole blood-derived
3522-0 Total number of discards: Plasma: Whole blood-derived: Psoralen- and Riboflavin-treated
3490-0 Total number of discards: Platelets: Apheresis
3513-9 Total number of discards: Platelets: Apheresis: Psoralen- and Riboflavin-treated
3484-3 Total number of discards: Platelets: Whole blood-derived
3504-8 Total number of discards: Platelets: Whole blood-derived: Psoralen- and Riboflavin-treated
3477-7 Total number of discards: Red Blood Cells: Apheresis
3555-0 Total number of discards: Red Blood Cells: Apheresis: S-303- and Riboflavin-treated
3470-2 Total number of discards: Red Blood Cells: Whole blood-derived
3546-9 Total number of discards: Red Blood Cells: Whole blood-derived: S-303- and Riboflavin-treated
3469-4 Total number of discards: Whole Blood
3433-0 Total number of units transfused: Cryoprecipitate
3562-6 Total number of units transfused: Cryoprecipitate: Psoralen- and Riboflavin-treated
3431-4 Total number of units transfused: Plasma: Apheresis
3529-5 Total number of units transfused: Plasma: Apheresis: Psoralen- and Riboflavin-treated
3429-8 Total number of units transfused: Plasma: Whole blood-derived
3520-4 Total number of units transfused: Plasma: Whole blood-derived: Psoralen- and Riboflavin-treated
3421-5 Total number of units transfused: Platelets: Apheresis
3511-3 Total number of units transfused: Platelets: Apheresis: Psoralen- and Riboflavin-treated
3417-3 Total number of units transfused: Platelets: Whole blood-derived
3502-2 Total number of units transfused: Platelets: Whole blood-derived: Psoralen- and Riboflavin-treated
3409-0 Total number of units transfused: Red Blood Cells: Apheresis
3553-5 Total number of units transfused: Red Blood Cells: Apheresis: S-303- and Riboflavin-treated
3401-7 Total number of units transfused: Red Blood Cells: Whole blood-derived
3544-4 Total number of units transfused: Red Blood Cells: Whole blood-derived: S-303- and Riboflavin-treated
3467-8 Total number of units transfused: Whole Blood
3539-4 Total patients transfused
2036-2 Toxigenic culture
2304-4 Transient patient
1117-1 Tunneled (dialysis)
1118-9 Tunneled (other than dialysis)
1116-3 Umbilical
1622-0 Upper respiratory tract infection, pharyngitis, laryngitis, epiglottitis
3191-4 Urinary catheter present
1972-9 Urine not tested for white blood cells
1624-6 Vaginal cuff infection
2141-0 Vaginal hysterectomy
2319-2 Vascular access
2323-4 Vascular site fistula
2324-2 Vascular site graft
2343-4 Ventilator-associated condition (VAC)
2340-3 Ventilator-associated event (VAE)
2142-8 Ventricular shunt
2053-7 Verona integron-encoded metallo-beta-lactamase
1606-3 Vertebral disc space infection
1335-9 Very preterm (28 to <32 weeks)
1922-4 Wheezing, rales or rhonchi
2331-7 Where was the positive blood culture collected
2349-9 White blood cell count >=12,000 or <=4,000 cells/mm3
1958-8 Worsening gas exchange
2320-0 Wound (not related to vascular access) with pus or increased redness
1649-3 Wrong implant
1648-5 Wrong patient
1647-7 Wrong side
1646-9 Wrong site